Showing 3011-3020 of 3288 results for "".
- CVS Pharmacy's New Long Live Skin Campaign Aims to Increase Awareness of Skin Healthhttps://practicaldermatology.com/news/cvs-pharmacys-new-long-live-skin-campaign-aims-to-increase-awareness-of-skin-health/2458183/CVS Pharmacy, the retail division of CVS Health, is rolling out a new multi-platform Long Live Skin campaign to increase awareness about skin health, sun safety and proper skincare. The Long Live Skin Campaign kicks off today online&nbs
- Coolibar Gets Gross To Prevent Skin Cancerhttps://practicaldermatology.com/news/coolibar-gets-gross-to-prevent-skin-cancer/2458206/Sun protective clothing and accessory maker Coolibar’s new skin cancer prevention and awareness campaign may make you sick, and that’s kind of the point. Called "Let's Get Gross," the new campaign will feature stories f
- Novan Forms New Advisory Council Focused on Nitric Oxide Technologies in Dermatologyhttps://practicaldermatology.com/news/novan-forms-new-advisory-council-focused-on-nitric-oxide-technologies-in-dermatology/2458228/Novan, Inc. has formed an Advisory Council comprised of key opinion leaders with broad expertise in dermatology. These leading physicians will provide medical advice and drug-development insight to the Company’s senior leadership team and board of directors. The Advisory Council will
- Education Credits Available: ABCs of Nitric Oxide in the Skinhttps://practicaldermatology.com/news/education-credits-available-abcs-of-nitric-oxide-in-the-skin/2458239/A free, online educational program intended to provide participants increased knowledge regarding the role of NO in maintaining a variety of physiologic processes has been launched. The program is directed by James Q. Del Rosso, DO. The program is also intended to address the correlation of
- Serlopitant May Stop the Itch of Prurigo Nodularishttps://practicaldermatology.com/news/serlopitant-may-stop-the-itch-of-prurigo-nodularis/2458252/Menlo Therapeutics Inc.’s Serlopitant performed well in phase 2 trial (TCP-102) evaluating it as a treatment of pruritus associated with prurigo nodularis, successfully meeting its primary efficacy endpoint and key sec
- Mosquito Virus Expert Discusses a Promising New Drug For Zikahttps://practicaldermatology.com/news/mosquito-virus-expert-discusses-a-promising-new-drug-for-zika/2458257/Thomas Voss, PhD, a world-renowned leader in infectious disease research, and his team, say there are two strategies for developing a defense program against Zika infection: prevention, achieved by developing an effective vaccine and vaccination program or the development of a drug that can kill
- Pierre Fabre and Hill Dermaceuticals Partner in Commercial Partnership for TOLAK for AKshttps://practicaldermatology.com/news/pierre-fabre-and-hill-dermaceuticals-partner-in-commercial-partnership-for-tolak-for-aks/2458258/Pierre Fabre Dermo-Cosmetique and Hill Dermaceuticals, Inc. have entered into a strategic commercial partnership for TOLAK, a patented prescription dermatologic drug, indicated for the topical treatment of actinic keratosis lesions of the face, ears, and/or scalp. Under the terms of the a
- New From Skinceuticals: H.A. Intensifierhttps://practicaldermatology.com/news/new-from-skinceuticals-ha-intensifier/2458285/SkinCeuticals is rolling out their new H.A. Intensifier, a corrective hyaluronic acid serum. Key ingredients include 10% Proxylane, a proprietary ingredient, to support hyaluronic acid levels and
- Crescita Therapeutics Announces Management and Board Changeshttps://practicaldermatology.com/news/crescita-therapeutics-announces-management-and-board-changes/2458293/Crescita Therapeutics Inc., a commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, introduced Ms. Muneerah Kanji, MBA, CPA, CA, Crescita's Corporate Controll
- Dermavant Licenses Portola Pharma's Cerdulatinib For Skin Applicationshttps://practicaldermatology.com/news/dermavant-licenses-portola-pharmas-cerdulatinib-for-skin-applications/2458338/Dermavant Sciences has licensed cerdulatinib from Portola Pharma for topical dermatologic applications. Cerdulatinib is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that Portola is developing to treat patients